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Chemotherapy-induced peripheral neuropathy (CIPN) is one of the
most common side effects encountered in patients treated with
chemotherapeutic drugs binding to soluble tubulin or targeting
microtubules.1,2 Some of these drugs, such as taxanes and
ixabepilone, stabilize and block microtubule remodeling, whereas
others, including Vinca alkaloids, colchicine and eribulin, promote
microtubule disassembly.3 Over the last few years, the use of
antibody-drug conjugates (ADCs) with potent and highly speciﬁc
activity against protein targets, which are abundantly expressed
on malignant cells, has greatly improved the outcome of patients
with cancer. Among ADCs used in patients with hematologic
cancer, an anti-CD30 chimeric antibody conjugated by a protease-
cleavable dipeptide to monomethyl auristatin E (MMAE; a
synthetic agent that blocks polymerization of tubulin), named as
brentuximab vedotin (BV), has demonstrated efﬁcacy in the
treatment of relapsed or refractory Hodgkin’s lymphoma (HL) and
systemic anaplastic large-cell lymphoma.4–6 Neurotoxicity is the
greatest concern regarding BV, and the most frequent complica-
tion is peripheral neuropathy (PN), which often causes disconti-
nuation of therapy.6–11 The mechanisms responsible for
neuropathy remain unknown, as peripheral nerves do not express
CD30, thus apparently precluding the targeted delivery of MMAE
to nerve ﬁbers. However, it is unknown whether untargeted or
systemic delivery of ADC and/or free MMAE to neuronal bodies
and their axonal extensions may occur.12 To date, no studies are
available on morphological and ultrastructural changes occurring
in peripheral nerves of patients with BV-related PN. Among
patients with HL in treatment with BV, who are referred to our
clinic for neurological evaluation and electrophysiological inves-
tigations, we recently had the opportunity to study a patient with
severe neuropathy and to investigate pathological changes at
sural nerve biopsy.
A 22-year-old man affected with HL, diagnosed in 2009, was
treated with doxorubicin, bleomycin, vinblastine and dacarbazine
followed by BEACOPP, local mediastinal radiotherapy and auto-
logous stem-cell transplantation. In January 2012, allogeneic bone
marrow transplantation was performed, and on February 2013 he
was started on BV at the standard intravenous dose of 1.8 mg/kg
every 3 weeks for up to 16 cycles. After the seventh cycle, the
patient developed progressive weakness of both legs and he
walked only with forearm crutches. Two months later he began to
complain of distal numbness in the hands and feet; nevertheless,
the treatment was completed without dose modiﬁcation or delay.
In March 2014, owing to rapid progression of weakness over the
2 months following completion of BV cycles, the patient was sent
to our clinic for neurological evaluation and neurophysiological
testing. Ambulation with crutches revealed a steppage gait, more
severe on the right. On testing of muscle strength there was 3/5
strength with elbow and wrist ﬂexion/extension on Medical
Research Council scale, and 2/5 with hand grip; knee ﬂexion and
extension were 3/5, ankle dorsiﬂexion showed 0/5 strength and
ankle ﬂexion 1/5. The patient had paresthesias and dysethesias in
both hands and feet; sensory responses to light touch, pinprick
and temperature were intact. There was decreased vibratory
sensation in a bilateral glove-and-stocking distribution, more
marked distally. The deep-tendon reﬂexes were abolished in the
lower and upper limbs. Neurophysiological testing showed
changes consistent with severe predominantly motor neuropathy;
the peroneal and tibial motor responses were not recordable,
whereas reduced sensory sural nerve responses were obtained
on both sides. Motor nerve conduction studies yielded a mild
increase in distal motor latencies of median nerves with severe
reduction of compound muscle action potential, more on the
right, whereas ulnar nerves were less affected. The sensory
conduction studies of the median and ulnar nerves displayed
reduced amplitudes and nearly 30% reduction of normal age
values in conduction velocities (CVs).
Given the rapid progression and severity of the neuropathy and
the ﬁndings of nerve conduction studies, a sural nerve biopsy was
performed. Plastic-embedded sections of the biopsy specimen
showed features of active axonal neuropathy with decreased
density of myelinated ﬁbers of all calibers, ongoing wallerian-like
degeneration and sporadic small clusters of regenerating ﬁbers, in
the absence of cellular inﬂammation (Figure 1a). Electron
microscopical examination revealed alterations in axonal cytoske-
leton, altered orientation of microtubules (MT) and severe
decrease in identiﬁable MT proﬁles in myelinated (Figures 1b
and c), and to a lesser extent, in unmyelinated ﬁbers, as compared
with control axons (Figure 1d). Determination of the number of
MT was obtained by direct count in a total of 30 myelinated axons
from the patient’s sural nerve and 30 control axons, as previously
described.13 After counting all MT in randomly sampled axons, we
found that the median MT density was 1.3/μm2 (range 0.3–7.6) in
the case index, as opposed to 9.9/μm2 (range 7.1–17.5) in control
ﬁbers. In addition to MT loss, some axons showed a spatial
disorganization of neuroﬁlaments and a variable increase in
smooth endoplasmic reticulum and membranous organelles,
ﬁndings suggestive of an impairment of fast anterograde
transport. Over the next 5 months, an improvement in ambulation
and muscle strength in both hands was observed, with restoration
of biceps and triceps reﬂexes; decrease in paresthesias was also
reported. An improvement in motor and sensory functions, mostly
in the upper limbs, was further observed 7 months later, in
keeping with neurophysiological ﬁndings revealing an increase of
nerve CVs and amplitudes.
During the course of treatment with BV, the patient here
reported developed sensorimotor axonal neuropathy, a complica-
tion that was somewhat expected given its reported high
frequency in patients exposed to BV and polatuzumab
vedotin.6,9,14 The onset was subacute and characterized by slightly
asymmetric weakness that predominantly affected lower extre-
mity extensors, leading to foot drop and impaired ambulation, in
addition to involvement of upper extremities with marked
reduction of grip strength. Within few weeks, motor events were
followed by sensory manifestations, including paresthesias and
loss of large ﬁber sensory modalities in a length-dependent
pattern. No apparent autonomic dysfunction or light touch and
pinprick loss were observed, a ﬁnding suggestive of sparing of
small ﬁbers. Fourteen months after all 16 cycles were completed,
a slight improvement of signs and symptoms was noted, although
the occurrence of muscular atrophy and sensory loss are likely to
be considered permanent events. The absence of conditions
predisposing to PN, in addition to the occurrence of manifesta-
tions during treatment and the temporal evolution of the
sensorimotor changes, suggest a causal association between BV
administration and the neurotoxic complication; nevertheless, the
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contribution of antecedent chemotherapies cannot be completely
ruled out. Similarly to other CIPN, BV-induced PN is characterized
by a length-dependent axonopathy, with early changes occurring
at the distal sites and ensuing spread to more proximal locations,
a pattern coherent with the dying back model. At variance with
previous investigations, reporting a high frequency of sensory
symptoms at neuropathy onset,7–9 in our case the presentation
was that of a motor axonal neuropathy with asymmetric features.
Indeed, sensory signs and symptoms occurred only several weeks
later, thus suggesting that still unknown factors may have a role in
the selective vulnerability of different neuronal populations. The
occurrence of graded, symmetric sensory loss with a length-
dependent pattern, in addition to the detection of small clusters
of regenerating ﬁbers in the obtained nerve biopsy, is further
indicative of distal axonal degeneration, and apparently rules out
a neurotoxic effect at the level of sensory neurons residing in
dorsal root ganglia. Although the exact mechanisms of BV-
induced PN remain to be elucidated, it is reasonable to suggest
that damage to peripheral axons may be the consequence of its
effects on MT polymerization. This hypothesis is supported by
pathological changes encountered in PN induced by vincristine, a
Vinka alkaloid drug that impedes polymerization of tubulin into
MT. Indeed, previous experimental work has demonstrated that in
vincristine-induced PN there is a decreased total number and
density of axonal MT in myelinated sensory axons, in addition to
altered MT orientation and arrangement.15 These MT abnormal-
ities interfere with fast axonal transport, an intracellular bidirec-
tional system devoted to the anterograde supply of cytoskeletal/
membrane components, organelles and protein particles to axon
terminals, and retrograde delivery of endosome and gene
expression signals to the neuronal cell body. A comparable effect
of BV and other ADCs bearing vedotin has been claimed in the
pathogenesis of PN, however, no investigations are available to
date. Although the pathological study of a single case represents a
major limitation of our report, the present demonstration of
severe MT loss in myelinated ﬁbers of the sural nerve in a patient
with BV-associated PN, strongly conﬁrms that the neurotoxicity of
this ADC is exerted through disruption of axonal MT. In addition to
MT loss, some axons showed a spatial disorganization of
neuroﬁlaments and variable increase in smooth endoplasmic
reticulum and membranous organelles, ﬁndings suggestive of an
impairment of fast anterograde transport. How peripheral nerves
are exposed to antibody-conjugated MMAE or free MMAE remains
to be clariﬁed. In previous studies, a similar pharmacokinetic
proﬁle for vedotin-bearing ADCs and unconjugated MMAE was
found, with steady state occurring by 21 days; notably, the
concentration of BV was much higher than MMAE.8 Therefore,
untargeted delivery or diffusion of BV to peripheral nerves, or a
bystander effect, following detachment of MMAE from the
antibody, may account for exposure of the axonal cytoskeleton
to this microtubule’s ‘Apollyon’.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
This work was supported in part by research grant 2014 from the University of
Verona.
Figure 1. (a) A Spurr-embedded section of the sural nerve biopsy specimen shows reduction in density of myelinated ﬁbers, degenerating
axons and a few regenerating clusters, ﬁndings consistent with ongoing axonal neuropathy (scale bar= 50 μm). (b) High magniﬁcation
electron micrograph of a myelinated axon of the patient’s sural nerve shows a few microtubule proﬁles oriented along the longitudinal axis of
the ﬁber (arrowhead), in addition to tangentially oriented microtubules (arrow; scale bar= 300 nm). (c) A myelinated ﬁber showing severe
depletion of microtubules, bundles of misaligned neuroﬁlaments and subaxolemmal segregation of smooth endoplasmic reticulum and
membranous organelles (scale bar= 120 nm). (d) A control myelinated ﬁber showing the typical alignment of the axonal cytoskeleton and the
distribution of microtubules in distinct microdomains (scale bar= 120 nm).
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